EGFR inhibitors have been tested in ovarian cancer with response rates of 10% or less [15]–[17]; however, none of these studies prospectively tested ovarian cancers for EGFR mutations, a practice now routinely done for non-small cell lung cancer that has resulted in the molecularly targeted use of EGFR inhibitors. This evidence concerns the gene EGFR and ovarian cancer.